Orphazyme Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$263.3M
Lead Investor(s):N/A

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Orphazyme's estimated annual revenue is currently $32.2M per year.(?)
  • Orphazyme's estimated revenue per employee is $155,000
  • Orphazyme's total funding is $263.3M.

Employee Data

  • Orphazyme has 208 Employees.(?)
  • Orphazyme grew their employee count by 51% last year.
  • Orphazyme currently has 1 job openings.

Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases, including sporadic Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), Niemann Pick Type C (NPC), and Gaucher. Anticipated completion of three potential registration studies by end 2020, with the first potential marketing authorization in 2020.